Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
Frances H. Priddy, Michael Williams, Simon Carson, Brittany Lavender, Julia Mathieson, Chris Frampton, View ORCID ProfileNicole J. Moreland, Reuben McGregor, Georgia Williams, Maia Brewerton, Katie Gell, James Ussher, Graham Le Gros
doi: https://doi.org/10.1101/2022.04.05.22273480
Frances H. Priddy
1Vaccine Alliance Aotearoa New Zealand and Malaghan Institute of Medical Research, Wellington New Zealand
Michael Williams
2Pacific Clinical Research Network, Rotorua and Christchurch New Zealand
Simon Carson
2Pacific Clinical Research Network, Rotorua and Christchurch New Zealand
Brittany Lavender
1Vaccine Alliance Aotearoa New Zealand and Malaghan Institute of Medical Research, Wellington New Zealand
Julia Mathieson
2Pacific Clinical Research Network, Rotorua and Christchurch New Zealand
Chris Frampton
3University of Otago, Christchurch New Zealand
Nicole J. Moreland
4University of Auckland, Auckland New Zealand
Reuben McGregor
4University of Auckland, Auckland New Zealand
Georgia Williams
2Pacific Clinical Research Network, Rotorua and Christchurch New Zealand
Maia Brewerton
1Vaccine Alliance Aotearoa New Zealand and Malaghan Institute of Medical Research, Wellington New Zealand
5Department of Clinical Immunology & Allergy, Auckland City Hospital, Auckland NZ
Katie Gell
1Vaccine Alliance Aotearoa New Zealand and Malaghan Institute of Medical Research, Wellington New Zealand
James Ussher
6Vaccine Alliance Aotearoa New Zealand and University of Otago, Dunedin New Zealand
Graham Le Gros
1Vaccine Alliance Aotearoa New Zealand and Malaghan Institute of Medical Research, Wellington New Zealand
Article usage
Posted April 06, 2022.
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
Frances H. Priddy, Michael Williams, Simon Carson, Brittany Lavender, Julia Mathieson, Chris Frampton, Nicole J. Moreland, Reuben McGregor, Georgia Williams, Maia Brewerton, Katie Gell, James Ussher, Graham Le Gros
medRxiv 2022.04.05.22273480; doi: https://doi.org/10.1101/2022.04.05.22273480
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
Frances H. Priddy, Michael Williams, Simon Carson, Brittany Lavender, Julia Mathieson, Chris Frampton, Nicole J. Moreland, Reuben McGregor, Georgia Williams, Maia Brewerton, Katie Gell, James Ussher, Graham Le Gros
medRxiv 2022.04.05.22273480; doi: https://doi.org/10.1101/2022.04.05.22273480
Subject Area
Subject Areas
- Addiction Medicine (317)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2302)
- Dermatology (205)
- Emergency Medicine (372)
- Epidemiology (11640)
- Forensic Medicine (10)
- Gastroenterology (686)
- Genetic and Genomic Medicine (3640)
- Geriatric Medicine (342)
- Health Economics (625)
- Health Informatics (2337)
- Health Policy (921)
- Hematology (337)
- HIV/AIDS (761)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3395)
- Nursing (193)
- Nutrition (512)
- Oncology (1784)
- Ophthalmology (528)
- Orthopedics (212)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1014)
- Primary Care Research (411)
- Public and Global Health (6037)
- Radiology and Imaging (1238)
- Respiratory Medicine (815)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (144)